Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL

Jinrong Cheng, Bonnie L. Hylander, Maria R. Baer, Xing Chen, Elizabeth A. Repasky

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Targeting death receptors with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has the remarkable potential to selectively kill malignant cells whereas normal cells are largely unaffected by this treatment. However, some tumor cells, including leukemia cells, exhibit resistance to this molecule. To investigate the basis for resistance of leukemia cells to the zinc-bound form of Apo2 ligand (Apo2L)/TRAIL, which is currently being evaluated in clinical trial, we isolated several resistant HL60 clones from parental HL60 cells by selection using the recombinant Apo2L/TRAIL. Differing resistance mechanisms were identified and characterized in these Apo2L/ TRAIL-resistant clones. In one case, the level of the cell-surface death receptor DR4, but not DR5, was significantly decreased. However, these cells did undergo apoptosis in response to another form of recombinant TRAIL, histidine-tagged TRAIL, suggesting differing contributions of DR4 and DR5 in the response to these two forms of TRAIL. In the case of other clones, expression of procaspase-8 protein was lost and this was associated with a novel Leu22→Phe22 point mutation in CASP-8 gene. These results show that cells within a given tumor can have widely distinct mechanisms underlying resistance to Apo2L/TRAIL.

Original languageEnglish (US)
Pages (from-to)1844-1853
Number of pages10
JournalMolecular Cancer Therapeutics
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Leukemia
Ligands
Death Domain Receptors
Clone Cells
Apoptosis
Caspase 8
HL-60 Cells
Cell Surface Receptors
Point Mutation
Histidine
Zinc
Neoplasms
Cell Death
Tumor Necrosis Factor-alpha
Clinical Trials
Genes
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. / Cheng, Jinrong; Hylander, Bonnie L.; Baer, Maria R.; Chen, Xing; Repasky, Elizabeth A.

In: Molecular Cancer Therapeutics, Vol. 5, No. 7, 01.07.2006, p. 1844-1853.

Research output: Contribution to journalArticle

Cheng, Jinrong ; Hylander, Bonnie L. ; Baer, Maria R. ; Chen, Xing ; Repasky, Elizabeth A. / Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. In: Molecular Cancer Therapeutics. 2006 ; Vol. 5, No. 7. pp. 1844-1853.
@article{37a896c93abf47f784037c78011cb6ce,
title = "Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL",
abstract = "Targeting death receptors with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has the remarkable potential to selectively kill malignant cells whereas normal cells are largely unaffected by this treatment. However, some tumor cells, including leukemia cells, exhibit resistance to this molecule. To investigate the basis for resistance of leukemia cells to the zinc-bound form of Apo2 ligand (Apo2L)/TRAIL, which is currently being evaluated in clinical trial, we isolated several resistant HL60 clones from parental HL60 cells by selection using the recombinant Apo2L/TRAIL. Differing resistance mechanisms were identified and characterized in these Apo2L/ TRAIL-resistant clones. In one case, the level of the cell-surface death receptor DR4, but not DR5, was significantly decreased. However, these cells did undergo apoptosis in response to another form of recombinant TRAIL, histidine-tagged TRAIL, suggesting differing contributions of DR4 and DR5 in the response to these two forms of TRAIL. In the case of other clones, expression of procaspase-8 protein was lost and this was associated with a novel Leu22→Phe22 point mutation in CASP-8 gene. These results show that cells within a given tumor can have widely distinct mechanisms underlying resistance to Apo2L/TRAIL.",
author = "Jinrong Cheng and Hylander, {Bonnie L.} and Baer, {Maria R.} and Xing Chen and Repasky, {Elizabeth A.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0050",
language = "English (US)",
volume = "5",
pages = "1844--1853",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL

AU - Cheng, Jinrong

AU - Hylander, Bonnie L.

AU - Baer, Maria R.

AU - Chen, Xing

AU - Repasky, Elizabeth A.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Targeting death receptors with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has the remarkable potential to selectively kill malignant cells whereas normal cells are largely unaffected by this treatment. However, some tumor cells, including leukemia cells, exhibit resistance to this molecule. To investigate the basis for resistance of leukemia cells to the zinc-bound form of Apo2 ligand (Apo2L)/TRAIL, which is currently being evaluated in clinical trial, we isolated several resistant HL60 clones from parental HL60 cells by selection using the recombinant Apo2L/TRAIL. Differing resistance mechanisms were identified and characterized in these Apo2L/ TRAIL-resistant clones. In one case, the level of the cell-surface death receptor DR4, but not DR5, was significantly decreased. However, these cells did undergo apoptosis in response to another form of recombinant TRAIL, histidine-tagged TRAIL, suggesting differing contributions of DR4 and DR5 in the response to these two forms of TRAIL. In the case of other clones, expression of procaspase-8 protein was lost and this was associated with a novel Leu22→Phe22 point mutation in CASP-8 gene. These results show that cells within a given tumor can have widely distinct mechanisms underlying resistance to Apo2L/TRAIL.

AB - Targeting death receptors with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has the remarkable potential to selectively kill malignant cells whereas normal cells are largely unaffected by this treatment. However, some tumor cells, including leukemia cells, exhibit resistance to this molecule. To investigate the basis for resistance of leukemia cells to the zinc-bound form of Apo2 ligand (Apo2L)/TRAIL, which is currently being evaluated in clinical trial, we isolated several resistant HL60 clones from parental HL60 cells by selection using the recombinant Apo2L/TRAIL. Differing resistance mechanisms were identified and characterized in these Apo2L/ TRAIL-resistant clones. In one case, the level of the cell-surface death receptor DR4, but not DR5, was significantly decreased. However, these cells did undergo apoptosis in response to another form of recombinant TRAIL, histidine-tagged TRAIL, suggesting differing contributions of DR4 and DR5 in the response to these two forms of TRAIL. In the case of other clones, expression of procaspase-8 protein was lost and this was associated with a novel Leu22→Phe22 point mutation in CASP-8 gene. These results show that cells within a given tumor can have widely distinct mechanisms underlying resistance to Apo2L/TRAIL.

UR - http://www.scopus.com/inward/record.url?scp=33747623259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747623259&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0050

DO - 10.1158/1535-7163.MCT-06-0050

M3 - Article

C2 - 16891471

AN - SCOPUS:33747623259

VL - 5

SP - 1844

EP - 1853

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -